EU officials say fines pending for Lundbeck, Servier; Bayer wins OK for Flexyess contraceptive;

@FiercePharma: Scotland rejects Avastin for ovarian cancer. Roche says the Scots need a cancer-drugs fund like England's. Report | Follow @FiercePharma

> European regulators said they will decide next year whether to fine Denmark's Lundbeck and France's Servier for antitrust violations related to generic versions of their drugs. Report

> Bayer won European approval for its new contraceptive combination drug Flexyess, which comprises drospirenone and ethinylestradiol. Report

> Questcor ($QCOR) said prescriptions for its Acthar product amounted to about 520 in September, compared with about 630 in August. Report

> India's Dr Reddy's expanded its manufacturing operations in the U.K. to increase production of active pharmaceutical ingredients for drug development. Report

> India's Piramal Healthcare is eyeing acquisitions in the U.S. and Europe to expand its contract research and manufacturing operations. Report

> Expired drugs were found to retain their potency in a new study, prompting calls to reconsider expiration-date policies in an attempt to save money on drugs. Report

> Baxter International ($BAX) says it expects earnings to increase by 7% to 9% over the next 5 years as sales grow by 5% annually. Report

Medical Device News

 @FierceMedDev: AngioDynamics has agreed to purchase Vortex Medical for $55M. News | Follow @FierceMedDev

 @MarkHFierce: Stem cells derived from skin to be tested in humans as eye disease treatment--via Bloomberg. Article | Follow @MarkHFierce

 @DamianFierce: Boston Scientific will pay up to $265M for Rhythmia Medical. News | Follow @DamianFierce

> St. Jude may lose defibrillator lead partner. Story

> Accutron recalls flowmeters over gas risk. Item

Biotech News

 @FierceBiotech: Fight against 'unwarranted' drug patents goes online. FierceBiotechIT article | Follow @FierceBiotech

 @JohnCFierce: Interesting. Twitter conclusion: Solanezumab a complete bust. But on BMBG, Reuters etc., it's an intriguing "win" for patients. Disconnect. | Follow @JohnCFierce

 @RyanMFierce: Magic Johnson is using his celebrity to bring attention to OraSure's at-home HIV test. A good use of his celebrity, I think.  | Follow @RyanMFierce

> Merck to shutter longtime NJ HQ in corporate reshuffle. News

> Billionaire Kirk orchestrates $45M cell therapy tie-up in biotech deal spree. Story

> Merck taps startup from Down Under for vaccine patch. Article

> Eli Lilly surges on conflicting data for Alzheimer's drug solanezumab. Report

Pharma Manufacturing News

> Compounder tied to meningitis deaths sold large quantities. News

> Sanofi Pasteur reports more issues with vaccine quality. Story

> Mold found in Hospira dextrose solution. Report

Biotech Research News

> Japanese scientists weld stem cells to create eggs and then baby mice. More

> RXi gains SBIR grant to pursue RNAi eye cancer drug. News

> Athersys stem cell therapy displays power as MS treatment. Article

> Inovio preclinical results prove skin delivery potency for DNA vaccines. Story

And Finally... Novartis ($NVS) launched a YouTube talk show about advanced breast cancer. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.